Αποτελέσματα Αναζήτησης
16 Οκτ 2019 · The two great challenges in translational research for Herpes simplex virus are prevention of initial genital herpes and suppression of recurrent herpes, by prophylactic vaccines and either antivirals or immunotherapeutic vaccines respectively.
Our results of immunotherapy with GEN-003, a novel vaccine for genital herpes, composed of HSV-2 gD2ΔTMR and a fragment of ICP4 protein (ICP4.2) adjuvanted with Matrix-M2, demonstrate that it had an acceptable safety profile, was immunogenic, and reduced both recurrent viral shedding and the number of days with lesions at doses of 30 µg and ...
This review focuses on conventional methods for evaluating the efficacy of a herpes vaccine using differential CD8 + T cells and important unaccounted immune aspects for designing an effective vaccine against herpes.
24 Απρ 2022 · Introduction. According to the World Health Organization (WHO), over two-thirds of the worldwide population in infected with HSV-1 (commonly known to cause oral herpes or cold sores) and HSV-2 (commonly known to cause genital herpes) (1, 2).
6 Δεκ 2021 · Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in Guinea pigs compared to immunization with gD alone.
7 Δεκ 2021 · Within this article, we will review the current guidelines for the treatment of herpes simplex infections, our understanding of the immunological pathways involved, and novel vaccine candidates in development.
We also review what is known of the natural immune control of herpes lesions, via interacting innate immunity and CD4 and CD8 T cells and the lessons they provide for development of new, more effective vaccines.
